PRFX PRF Technologies Ltd.
Listings ·
Cash rose to $8,526 thousand at June 30, 2026, from $3,125 thousand at year end, while the six-month loss was $2,942 thousand. Most of the cash came from a $10.0 million equity line that has since ended.
The Standby Equity Purchase Agreement lets PRF sell up to $15.0 million of shares over 36 months at 97% of recent prices. Its 2026 going-concern paragraph and $3.1 million year-end cash sit beside the new line.
Nasdaq found PainReform complies with Rule 5550(b)(1), but warned that delisting could follow if the next periodic report does not show compliance.
The drug-delivery company is acquiring an AI solar analytics platform from BladeRanger Ltd. BladeRanger would receive 178,769 ordinary shares plus four sets of warrants, and the release gives no price or valuation for the business.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $17,000 | $0 |
| Research and development | $1.1 million | $11.7 million |
| Net income (loss) | -$5.0 million | -$14.6 million |
| Cash from operations | -$4.0 million | -$12.6 million |
| Cash and equivalents | $3.1 million | $4.3 million |
Our latest story on this, dated Apr 17, 2025: "PainReform (now PRF Technologies) says Nasdaq found it compliant with Rule 5550(b)(1)". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 18, 2026: "PRF Technologies signs $15.0 million equity line with Yorkville". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 18, 2025: "PainReform (now PRF Technologies) agrees to buy DeepSolar business for shares and warrants". The story links the filing or release it is based on. Read the story.
PRF Technologies Ltd. trades under the ticker PRFX on NASDAQ.
PRF Technologies Ltd. is listed on NASDAQ.
The SEC Central Index Key (CIK) for PRF Technologies Ltd. is 1801834. Its filings are on SEC EDGAR.
830,613 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-26.
Our directory records PRF Technologies Ltd. under Israel.
Our directory classifies PRF Technologies Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for PRF Technologies Ltd. is IL0011651580.
aibio.space lists PRF Technologies Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as L3.
$17,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
PRF Technologies Ltd. reported a net loss of $5.0 million for the fiscal year ended Dec 31, 2025, and used $4.0 million of cash in operations, per its annual report to the SEC.
$1.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a merger or acquisition agreement. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio